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Tuberculosis (TB) is the most deadly infectious disease in existence, and the only 
available vaccine, Bacillus Calmette-Guérin (BCG), is almost a century old and poorly 
protective. The immunological complexity of TB, coupled with rising resistance to anti-
microbial therapies, necessitates a pipeline of diverse novel vaccines. Here, we show 
that Bacillus subtilis spores can be coated with a fusion protein 1 (“FP1”) consisting 
of Mycobacterium tuberculosis (Mtb) antigens Ag85B, ACR, and HBHA. The resultant 
vaccine, Spore-FP1, was tested in a murine low-dose Mtb aerosol challenge model. 
Mice were primed with subcutaneous BCG, followed by mucosal booster immuniza-
tions with Spore-FP1. We show that Spore-FP1 enhanced pulmonary control of Mtb, as 
evidenced by reduced bacterial burdens in the lungs. This was associated with elevated 
antigen-specific IgG and IgA titers in the serum and lung mucosal surface, respectively. 
Spore-FP1 immunization generated superior antigen-specific memory T-cell proliferation 
in both CD4+ and CD8+ compartments, alongside bolstered Th1-, Th17-, and Treg-
type cytokine production, compared to BCG immunization alone. CD69+CD103+ tissue 
resident memory T-cells (Trm) were found within the lung parenchyma after mucosal 
immunization with Spore-FP1, confirming the advantages of mucosal delivery. Our data 
show that Spore-FP1 is a promising new TB vaccine that can successfully augment 
protection and immunogenicity in BCG-primed animals.
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inTrODUcTiOn
In 2015, tuberculosis (TB) overtook HIV/AIDS as the leading cause of death due to infection (1). 
This statistic contrasts starkly with the fact that the only available TB vaccine, Mycobacterium bovis 
Bacillus Calmette-Guérin (BCG), is the most widely administered vaccine in history (2), having been 
developed almost a century ago. The proposed reasons for the failure of BCG to adequately protect 
against TB are many and varied. They include (i) BCG sub-strain heterogeneity (3), (ii) pre-exposure 
of the host to environmental non-tubercle mycobacteria (4), (iii) a failure to prevent pulmonary 
infection (5), and (iv) limited protection in adults compared to children (6). Despite these limitations, 
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BCG is unlikely to be discontinued in clinical use. While its effi-
cacy in many demographics is modest, there are accumulating 
data indicating that BCG may protect against non-TB diseases by 
training the innate immune system to respond non-specifically to 
diverse microbial threats (7, 8). A novel TB vaccine is therefore 
likely to supplement, rather than replace, BCG.
In 2011, the novel viral vector TB vaccine MVA85A, comprising 
Ag85A, was tested for safety and efficacy in a phase 2 clinical trial 
in South Africa, and it was found that parenteral administration 
of MVA85A in BCG-immunized infants offered no significant 
protection above that of BCG alone (9). The reasons for its failure 
are still unclear, since MVA85A protected against Mycobacterium 
tuberculosis (Mtb) in multiple animal models (10). But it is 
becoming increasingly apparent that the development pipeline 
for new TB vaccines will require technological diversity in order 
to maximize chances of success. In recent years, vaccines that are 
based upon particulate nano- or microscale delivery systems have 
made remarkable strides in both oncology and infectious diseases 
(11–13).
Bacillus subtilis is an environmental Gram-positive bacterium 
that is also found as a gut commensal in humans (14). Its spores 
have the desirable properties of being both safe and adjuvantic 
(15). But more importantly, they possess hydrophobic and 
electrostatic properties that allow them to readily bind protein 
antigens, making these spores pertinent to vaccine development 
as potential antigen delivery systems (16). The combination of 
intrinsic adjuvanticity and antigen-binding biophysical proper-
ties allows B. subtilis spores to act simultaneously as adjuvants 
and antigen carriers. Studies have shown that immunization of 
mice with B. subtilis spores coated with the influenza antigen M2e 
can induce strong antibody responses and protect against lethal 
challenge (17, 18). Similar findings have been observed in other 
immunization models, including immunogenicity against HIV 
and streptococci (19, 20). B. subtilis spores are thus an attractive 
platform for subunit vaccine enhancement.
We have previously shown that B. subtilis spores coated 
with TB antigens (21) or genetically engineered to express a 
TB antigen (22) can enhance protection against TB by BCG 
(prime-boost) in a mouse intranasal infection model. Although 
this provided a proof-of-principle framework for vaccine efficacy, 
the use of genetically modified components in a vaccine presents 
numerous regulatory barriers for clinical application (23). Here, 
we developed a novel TB vaccine—“Spore-FP1”—composed of 
B. subtilis spores non-covalently coated with a fusion protein 
(FP1) consisting of the antigens Ag85B, ACR and the epithelium-
binding domain of HBHA (“FP1”). Ag85B and ACR were chosen 
to represent early and late stages of Mtb infection, respectively, 
while HBHA (heparin-binding domain only) was used for 
epithelial targeting in the lungs. Mucosal booster immunization 
with Spore-FP1 in BCG-primed mice enhanced protection in 
a low-dose aerosol Mtb challenge model, compared to BCG 
alone. The enhanced protection was concomitant with a wide 
array of boosted immunological parameters, including enhanced 
antigen-dependent T-cell proliferation and antibody production. 
Spore-FP1 is therefore a novel TB vaccine that has the potential to 
supplement pre-existing immunity conferred by BCG in human 
populations.
MaTerials anD MeThODs
ethics statement
All animals were used with approval from St. George’s University 
of London Ethics Committee under an approved Home Office 
animal project license (70/7490) and used in accordance with the 
Animals (Scientific Procedures) Act 1986.
Mice and immunizations
Female C57BL/6 mice were obtained from Charles River, UK, and 
were between 8 and 12 weeks of age before experimental use. For 
all bacterial challenge or immunogenicity experiments (except 
lung T-cell analysis), mice were immunized with 5 ×  105 CFU 
BCG Pasteur (100  µL) subcutaneously or vehicle control. 
Intranasal booster immunizations consisted of 1 × 109 B. subtilis 
spores coated with 10 µg FP1 in 40 µL volumes per animal per 
dose, or vehicle control. These immunizations were performed 
under light anesthesia. For experiments involving dead spores, 
spores were autoclaved before protein adsorption. For some 
experiments, the adjuvant poly(I:C) (Sigma-Aldrich) was used 
intranasally at a dose of 20 µg.
Mice were infected with approximately 200 M. tuberculosis 
bacilli per animal delivered via low-dose aerosol, using a Biaera 
aerosol generator (Biaera Technologies). Infectious dose was 
routinely verified by standard plating techniques.
Bacteria and colony Forming Unit 
Quantification
Bacillus Calmette-Guérin Pasteur and Mtb (strain H37Rv) were 
used for the in vivo experiments; these were kind gifts of Professor 
Juraj Ivanyi (King’s College, London). Both strains were grown 
to log phase at 37°C in 7H10 broth (Becton Dickinson) sup-
plemented with ADC (Becton Dickinson), 0.05% Tween-80 and 
Selectab (Mast Diagnostics). Bacteria were then enumerated by 
the standard CFU method on 7H11 agar plates [supplemented 
with OADC (Becton Dickinson), glycerol and Selectab (Mast 
Diagnostics)] and cryopreserved in liquid nitrogen until use.
Bacterial burden from mouse organs was assessed by CFU 
enumeration. Lung and spleen homogenates were prepared in 
a stomacher containing 0.1% Triton X-100. Homogenates were 
plated in technical duplicates (lungs) or singlets (spleens) on 
7H11 agar supplemented with OADC, glycerol and Selectatab. 
CFUs were counted after a 3–4-week incubation at 37°C.
Vaccines and immunization
Amino acid sequences of the Mtb proteins ACR, Ag85B (pos. 
23–25), and HBHA (pos. 160–199) were connected via linker 
peptides (GGGSGGGS), and six histidine residues were added 
to the C-terminus resulting in FP1. The amino acid sequence of 
FP1 was retranslated to DNA considering the codon usage of 
Escherichia coli DH5α, the host strain for protein production. 
In order to enable site-directed cloning, restriction sites for NcoI 
and HindIII were added to the 5′ and 3′ end, respectively. The 
synthetic gene was provided by GenScript (USA) inserted in 
pUC57. The gene of FP1 was excised from this plasmid using 
the abovementioned restriction endonucleases and ligated to 
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expression vector pLEXWO481, an IPTG-inducible derivative 
of pMV261 (24), digested with the same enzymes as before. 
For production of FP1, the gene was expressed under control of 
lac-promoter while growing the host strain in APS medium at 
30°C. Recombinant protein was isolated from inclusion bodies 
after denaturation in 8 M urea using metal chelate chromatog-
raphy (Ni-NTA Superflow, Qiagen). Highly enriched FP1 was 
refolded by gel-filtration using sephadex G-200 material (GE 
Healthcare). Purity was assessed by fully automated SDS-PAGE 
with fluorimetric detection and densitometric purity (>97% 
purity). Western blots specific for component antigens were used 
to confirm the identity of the protein band. Endotoxin content 
was measured by LAL assay and determined to be <7  IU/mg. 
For formulation, FP1 was incubated with spores for 1 h at room 
temperature prior to the addition of polyI:C (if used). Vaccines 
were delivered immediately after formulation.
antibody and antigen Quantification
Antibody levels (IgA and IgG) in BAL and serum were quantified 
by ELISA. Antigens [Ag855, ACR; Lionex GmbH (Braunschweig, 
Germany)] were coated onto a plate at 2 µg/mL overnight, fol-
lowed by blocking for 2 h with PBS containing 1% bovine serum 
albumin (BSA). BAL and serum were diluted 1:250 and 1:1,000, 
respectively, in PBS with 1% BSA and incubated on the plate 
in triplicate for 1 h at 37°C. Levels of IgA or IgG were detected 
using peroxidase-conjugated anti-mouse IgA or anti-mouse 
IgG (Sigma) and OPD substrate (Sigma). Plates were read on a 
Tecan200 plate-reader at 450 nm absorbance.
Assessment of protein loading onto spores and stability of final 
product was done by ELISA (quantifying unbound protein after 
adsorption) and by measuring charge and size using a ZetaSizer 
NanoZS (Malvern) according to manufacturer’s instructions and 
proprietary software. Significance was tested with a paired t-test. 
For ELISA measurements, FP1 was coated onto plates at varying 
concentrations as described for the antibody measurements, fol-
lowed by detection by a peroxidase-conjugated anti-His antibody 
(Sigma) in conjunction with OPD substrate. Plates were read as 
described above.
general Flow cytometry
For most experiments, cells were first stained with Fixable 
Viability Dye eFluor® 780 (1:1,000 dilution; eBioscience) in 
the presence of Fc receptor blockade (TruStain, 1:500 dilution; 
Biolegend). For surface staining, cells were then stained in flow 
cytometry buffer (PBS containing 0.5% BSA and 0.1% sodium 
azide—all from Sigma-Aldrich) for 30–45 min at 4°C. For some 
experiments, cells were subsequently fixed in the appropriate 
fixative for 30 min at 4°C, and then stained in a permeabilization 
buffer for 45 min, followed by acquisition on a BD FACSCanto 
II, unless otherwise specified. For compensation matrices, 
UltraComp beads were used according to the manufacturer’s 
instructions (eBioscience). Staining boundaries were determined 
by a combination of antibody titration, biological controls and 
fluorescence-minus-one samples.
antigen-Presenting cell (aPc) activation
Dendritic cells (DCs) were obtained according to a well-established 
protocol (25). Briefly, mouse femurs were aseptically flushed with 
complete RPMI (RPMI-1640 containing 100  U/mL penicillin/
streptomycin, 2 mM l-glutamine, 10% fetal calf serum, and 50 µM 
2-mercaptoethanol—all from Sigma-Aldrich) and the bone mar-
row cells were cultured in complete RPMI with 50 ng/mL GM-CSF 
(Peprotech) for 2 days, followed by complete removal of the liquid 
media containing non-adherent granulocytes, and replacement 
with fresh GM-CSF-supplemented media. Cells were then cultured 
for a further 3–4 days, and non-adherent and loosely adherent cells 
were gently detached. DCs were phenotyped by flow cytometry and 
were found to be>85% CD11c+ and expressing high levels of MHC 
Class II. DCs were cryopreserved in 10% DMSO until use. For 
experiments involving macrophages, the J774 cell line was used. 
Macrophages were cultured in complete DMEM (from Sigma, see 
RPMI), and sub-cultured every 3 days at ~80% confluency. Cells 
were>99% CD11b+ as assessed by flow cytometry.
To measure activation, APCs were stimulated for 48 h with B. 
subtilis spores at an MOI of 1, 10, or 100, or E. coli LPS (100 ng/mL; 
Sigma-Aldrich), and stained with a panel of antibodies: CCR7-
PerCP/Cy5.5, CD80-APC, CD86-PE/Cy7, MHC Class I-FITC, 
MHC Class II-Brilliant Violet 510, PD-L1-Brilliant Violet 421, 
and PD-L2-PE—all from Biolegend. Supernatants were tested 
for IL-1β, IL-6, and TNF-α. IL-12p40 was detected by intracel-
lular cytokine staining after 20  h stimulation of macrophages 
in the presence of 10 µg/mL brefeldin A (Sigma-Aldrich) using 
IL-12p40-PE (Biolegend) in flow cytometry buffer containing 
0.5% saponin (Sigma-Aldrich). To detect transcription factor 
phosphorylation, macrophages were stimulated for 4 h and then 
fixed in 90% methanol as previously described (26), followed by 
staining with antibodies against phosphorylated forms of c-Jun 
(AP-1), NF-κB (p60), and IRF-3 (Cell Signaling).
T-cell Proliferation
Splenocytes were obtained from mouse spleens that had 
been mechanically homogenized and treated with ACK lysis 
buffer (Sigma-Aldrich) to remove erythrocyte contamination. 
Splenocytes were cultured at 1  ×  106/well in a 96-well plate. 
Cells were stimulated with 5  µg/mL recall antigen or 1  µg/mL 
α-CD3 (Biolegend) for 5–6  days, followed by surface staining 
with CD4-PerCP/Cy5.5, CD8-Brilliant Violet 510, CD44-FITC, 
CD62L-PE, and CD90.2-Brilliant Violet 421—all from Biolegend. 
Cells were then fixed and permeabilized using the eBioscience 
Foxp3/Transcription Factor Staining Buffer Set and stained with 
Ki67-APC.
cytokine Quantification
Cytokines were measured by ELISA or Multiplex immunoassay. 
IL-1β, IL-6, and TNF-α in culture supernatant were measured 
by ELISA using eBioscience Ready-Set-Go kits according to the 
manufacturer’s instructions. For IL-4, IL-10, IL-17A, and IFN-γ, 
a 4-plex multiplex immunoassay (Biolegend) was used accord-
ing to manufacturer’s instructions. Data was acquired on a BD 
FACSCanto, and analysis performed using Legendplex software 
(Biolegend).
lung cell isolation and analysis
For these experiments, mice were immunized with PBS or 
BCG (subcutaneously) or mucosally with the indicated vaccine 
FigUre 1 | Spore-FP1 protects against aerosol Mycobacterium tuberculosis 
(Mtb) challenge. Mice received a Bacillus Calmette-Guérin subcutaneous 
prime (except the PBS control group) followed by two intranasal boosts with 
Spore-FP1. After 3 weeks, bacterial burdens in the lungs and spleens were 
quantified by CFU counting on 7H11 plates across three dilution ranges.  
(a) Mice were immunized with Spore-FP1 alone. (B) Mice were immunized 
with Spore-FP1 in combination with the adjuvant poly(I:C). Results are 
expressed as mean ± SEM. Data are derived from n = 4–7 individual mice. 
Significance was tested against the by one-way ANOVA with Tukey’s 
posttest, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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component. Lungs were perfused of blood by flushing PBS 
through the right ventricle. Tissue was then dissected into 1 mm 
pieces using a scalpel, followed by digestion in 1 mg/mL colla-
genase and 0.5 mg/mL DNase I (Roche). Cells were then passed 
through a 70  µm strainer (Becton Dickinson), contaminating 
erythrocytes were lysed, and mononuclear cells were stained for 
CD3-APC, CD4-PerCP/Cy5.5, CD8-Brilliant Violet 510, CD44-
FITC, CD62L-PE, CD69-PE/Cy7, and CD103-Brilliant Violet 
421—all from Biolegend.
statistical analysis
Statistical tests are described in the relevant figure legends. All 
analysis was performed using FlowJo v10, Microsoft Excel 2010 
and GraphPad Prism 7.
resUlTs
spores can effectively Bind to Mtb Fusion 
Proteins
We tested whether a biological carrier system, such as spores, could 
bind and facilitate carriage of the FP-1 fusion-protein. Spores 
were incubated with FP-1 prior to centrifugation to quantity the 
amount of free FP1 present in the supernatant after adsorption. 
Of 100 µg FP1, less than 2 µg free FP1 was detected in superna-
tants after adsorption indicating a high binding efficiency of over 
98% (n = 3). To characterize the formulated Spore-FP1 vaccine, 
we assessed the size and charge of Spores either pre- or postad-
sorption using a ZetaSizer NanoZS. Size of the spores increased 
following FP-1 adsorption from 1,337 ± 13.8 to 1,389 ± 13.53 nm 
for naked and loaded spores, respectively (n = 3). Spores became 
marginally more negative when FP-1 was loaded, with charge 
decreasing from −47.13 ± 0.95 to −49.1 ± 0.44 mv (n = 3). While 
neither of the changes were significant, both trended toward sig-
nificance (p = 0.064 and 0.068 for charge and size, respectively) 
and, in conjunction with the ELISA data, are suggestive of protein 
loading onto the spore surface. Importantly, FP1 loaded spores 
were moderately negatively charged and had a low polydispersity 
index (PDI = 0.237), indicating strong colloidal stability.
spore-FP1 can enhance Bacterial control 
afforded by Bcg
Mucosal vaccination against respiratory diseases offers distinct 
advantages over parenteral delivery routes, such as enhanced 
control of the pathogen, presumably due to localized immune 
effector cells (27). We therefore tested the ability of mucosally-
delivered Spore-FP1 to enhance control of Mtb, compared to 
BCG immunization alone, in a “prime-boost” strategy. We 
hypothesized that a booster immunization with Spore-FP1 
would lead to better protection than immunization with BCG 
alone. Mice were first primed with BCG or vehicle control, 
followed by two intranasal boosts with Spore-FP1. Mice were 
then challenged with ~100 CFU aerosolized Mtb, and bacterial 
burdens were quantified in the lungs and spleen. As shown in 
Figure 1A, mice immunized with BCG alone were better able to 
control Mtb compared to mock-immunized mice, as evidenced 
by reduced CFUs in the lungs (PBS CFUs: 5.54 ±  0.06; BCG 
CFUs: 4.84 ± 0.18, p < 0.05). When mice received the Spore-FP1 
booster immunization, however, there was a significant improve-
ment compared to BCG alone, with a near −1 log reduction in 
bacterial burden (Spore-FP1 CFUs: 4.10 ± 0.20, p < 0.0001 vs. 
PBS, p <  0.05 vs. BCG). In the spleens, BCG and Spore-FP1 
offered comparable levels of protection, with both groups exhi-
biting significant protection compared to mock immunization 
(p < 0.0001). Next, Spore-FP1 was tested with codelivery of the 
adjuvant poly(I:C), a known inducer of the Th1 subset when 
used in the respiratory tract (28). As can be seen in the lungs 
(Figure 1B), Spore-FP1 was again able to induce significantly 
better protection than BCG (p < 0.01), with a trend—though not 
a statistically significant difference—for increased protection in 
the spleen (p = 0.06, BCG vs. Spore-FP1). These data collectively 
demonstrate that Spore-FP1 immunization could improve pro-
tection offered by BCG alone in multiple contexts, and therefore 
FigUre 2 | Enhanced humoral immunity caused by Spore-FP1. Immunized 
mice were tested for the presence of antigen-specific IgG in the serum 
(1:1,000 dilution) and IgA in the BAL (1 mL PBS flush; 1:10 dilution) by 
ELISA, with optical density read at 450 nm in duplicate. (a) Levels of IgG and 
IgA specific to Ag85B. (B) Levels of IgG and IgA specific to ACR. Results are 
expressed as mean ± SEM. Data shown are derived from n = 3 individual 
mice and are representative of two independent experiments. Significance 
was tested against the unstimulated control by one-way ANOVA with Tukey’s 
posttest, *p < 0.05 and **p < 0.01.
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we sought to uncover any immunological phenomena that could 
be associated with efficacy.
spore-FP1 enhances antigen-specific 
antibody Production
Evidence suggests that antibodies may play a role in protect-
ing against TB, either directly (Fab-mediated) or indirectly 
(Fc-mediated): monoclonal IgA therapy can reduce pulmonary 
Mtb burden (29), and adoptive transfer of antibodies from hosts 
with latent TB can improve macrophage functionality (30). We 
therefore probed whether Spore-FP was generating antibodies 
against Ag85B and ACR. Spore-FP1 immunization significantly 
enhanced titers of Ag85B-specific IgA in the BAL compared 
to PBS (p <  0.05), whereas there was no difference with BCG 
(Figure 2A). There was also a trend for increased levels of Ag85B-
specific IgG induced by Spore-FP1. With regards to ACR-specific 
antibodies (Figure  2B), Spore-FP1 was able to significantly 
enhance levels of α-ACR IgG in the serum, compared to PBS 
(p < 0.01). However, there were no changes in the α-ACR IgA 
within the BAL.
spore-FP1 generates abundant Tcm and 
Tem cells with high Proliferative capacity
The observation that Spore-FP1 immunization led to higher 
Mtb-specific IgG and IgA titers suggested that T-cell immunity 
was also being modulated. We hypothesized that Spore-FP1 was 
inducing stronger T-cell immunity than BCG alone, leading to 
enhanced antibody levels. To test this, splenocytes from immu-
nized mice were assessed for the expression of the cell cycle and 
proliferation marker Ki67 after exposure to the recall antigens 
Ag85B, ACR and FP1. The Ki67+ cells were then divided into naive 
(CD44loCD62Lhi), T central memory (Tcm; CD44hiCD62Lhi) or T 
effector memory (Tem; CD44hiCD62Llo) phenotypes. As shown 
in Figure 3, as expected, there was minimal proliferation in the 
PBS group in response to all antigens, with a background level of 
~3% Ki67+ in memory cell subsets. There were modestly more 
proliferating cells in the BCG group, which is consistent with 
other studies showing that BCG induces a very small percentage 
of antigen-specific splenic T-cells (31, 32). For instance, there 
were 6.48% Ki67+ CD4+ Tem cells after ACR stimulation in 
this group, and a similar level in the CD8+ Tem cells. However, 
in the Spore-FP1 group, there was a sharp overall increase in 
the percentage of Ki67+ cells, with notable spikes (>20%) in 
proliferating CD8+ Tcm and Tem cells in response to Ag85B. 
Similarly, Spore-FP1 had the highest percentage of CD4+ Tem 
cells responding to Ag85B (>10%). Results for ACR in this group 
were more modest, but the trend remained consistent. These data 
support the ability of a mucosal vaccine to induce substantial 
T-cell responses at primary lymphoid sites.
spore-FP1 immunization results in a 
Mixed T-cell cytokine Profile
The increase in T-cell proliferation in response to mucosal 
immunization with Spore-FP1 led us to question which subsets 
of T helper cells and cytotoxic T-cells were responding to antigen. 
Therefore, splenocytes from immunized animals were cultured 
with recall antigens (Ag85B, ACR and FP1) and assessed for the 
production of IFN-γ, IL-4, IL-10, and IL-17A, which are secreted 
from Th1/Tc1, Th2/Tc2, Treg, and Th17/Tc17 subsets, respectively. 
We found (Figure 4) that there was muted cytokine production 
across all analytes in the BCG group when cells were stimulated 
with recall antigens, with the exception of minor IFN-γ secretion 
(570.36 pg/mL) after ACR pulsing. In the Spore-FP1 group, how-
ever, there was profound cytokine release in response to all three 
antigens. After Ag85B pulsing, Spore-FP1 splenocytes produced 
copious amounts of IFN-γ (3519.6 pg/mL), IL-10 (86.26 pg/mL), 
and IL-17A (1837.5 pg/mL), suggesting that Spore-FP1 immuni-
zation generated mixed T-cell subsets that were specific for Mtb 
antigens. Similar results were observed for FP1 antigen recall, 
and there were modest levels of cytokines for ACR. No IL-4 was 
detected in any of the groups.
evidence of Tissue-resident Memory 
T-cells after Mucosal immunization
Since Spore-FP1 was causing the development of antigen-specific 
T-cells in central lymphoid organs, we next interrogated the lungs 
for the presence of tissue-resident memory T-cells. Lungs were 
perfused and harvested from immunized animals, and then 
CD44hi (i.e., memory) T-cells were assessed for the expression 
of tissue retention markers CD69 and CD103. As shown in 
Figure 5, PBS and BCG immunization induced minimal levels 
FigUre 4 | Cytokine profiles during splenocyte antigen recall. Splenocytes from immunized mice were stimulated in technical duplicates with 5 µg/mL recall antigen for 
5–6 days and T-cell cytokines were measured by multiplex flow cytometry. Results are expressed as mean ± SEM. Data are derived from n = 3 pooled spleens per group.
FigUre 3 | Enhanced T-cell proliferation due to Spore-FP1. Splenocytes were incubated in technical duplicates with 5 µg/mL recall antigen for 5–6 days and proliferation 
was measured by Ki67 staining. A gating strategy of live cells→single cells→CD3+→CD4+/CD8+ was used, followed by gating for Ki67+ cells and determination of 
memory cell phenotype by expression of CD44 and CD62L. Results are expressed as mean ± SEM. Data are derived from n = 3 pooled spleens per group.
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of these cells (<4% in both CD4+ and CD8+ T-cells), with only 
a minor increase induced by FP1 alone. Notably, the mucosal 
delivery of B. subtilis spores alone did not lead to the generation 
of Trm, while the full vaccine construct, Spore-FP1, was able to 
induce 14.9% CD4+ and 12.5% CD8+ Trm, respectively.
Bacillus spores activate Macrophages 
and Dcs
Antigen-presenting cells are essential for the generation of T-cell 
immunity after immunization (33, 34). Empirical and systems 
biology approaches have revealed a correlation between APC 
activation by some antibody-inducing vaccines and protec-
tive immunity (35–37). Consequently, we next tested whether 
B. subtilis spores could activate DCs and macrophages (Figure 6). 
DCs and macrophages were pulsed with B. subtilis spores for 
2 days at a range of MOIs and assessed for the upregulation of 
maturation markers. In DCs, spores significantly upregulated 
CD80, MHC Class I and CCR7 (CD80: p < 0.05, MHC Class I: 
p < 0.001, CCR7: p < 0.01), with strong trends for upregulation 
of CD86 and PD-L1 (Figure 6A). Interestingly, spores induced 
FigUre 5 | Spore-FP1 induces enrichment of tissue resident memory cells. Mice were first immunized with Bacillus Calmette-Guérin for 6 weeks (except the PBS 
group) and then received two intranasal doses of either spores alone, fusion protein 1 (FP1) alone, or Spore-FP1. Lung parenchymal cells were assessed by flow 
cytometry for T-cell markers. A gating strategy of live cells→single cells→CD3+→CD4+/CD8+→CD44hiCD62Llo was used to measure the frequency of double-positive 
CD69/CD103 Trm. Data are derived from n = 3 pooled mice per group showing a representative plot.
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the downregulation of MHC Class II and PD-L2. This may reflect 
the time-point at which the markers were measured, since Class 
II is known to be upregulated initially, followed by late-phase 
downregulation in activated DCs (38). In macrophages, spores 
were able to induce the upregulation of PD-L1 (p < 0.05), PD-L2 
(p  <  0.001), and CCR7 (p  <  0.001), with similar trends for 
CD80, CD86, and MHC Class II. With regards to the production 
of proinflammatory cytokines, there was evidence of secretion 
of IL-6 and TNF-α at an MOI of 100 in DCs and macrophages 
(Figure  6B), albeit at lower levels compared to the positive 
control LPS. There was modest IL-1β production at the highest 
dose of spores. Next, we used intracellular cytokine staining to 
detect IL-12p40 production after spore exposure (Figure  6C). 
Spores were found to induce comparable levels of IL-12p40+ 
APCs (23.3%) compared to LPS (18.3%). As expected, there was 
minimal production of IL-12p40 in unstimulated cells. Finally, 
we investigated three transcription factors downstream of Toll-
like receptors (TLRs) to understand the cause of the phenotype. 
Intracellular flow cytometry at 4 h poststimulation (Figure 6D) 
revealed that B. subtilis spores were activating AP-1 (c-JUN), 
NF-κB and IRF-3 to a greater extent than LPS, suggesting 
engagement of both MyD88 and TRIF adaptors, in tandem with 
mitogen-activated protein kinase activity.
DiscUssiOn
Tuberculosis is a disease defined by an immunological complex-
ity that has hindered efforts toward vaccine development and 
allowed Mtb to persist perniciously across the globe. The cause of 
this complexity is a raft of exquisite immune evasion mechanisms 
that has evolved over thousands of years to manipulate host 
immunity. Therefore, at present, animal infection models are the 
most useful tool for predicting TB vaccine success (10).
We have previously reported that spores coated with Mtb 
antigens can provide good protection against Mtb in an intra-
nasal infection model (21). A major limitation of this model, 
however, is that intranasal infection is not physiologically 
representative of natural Mtb infection. Furthermore, this study 
did not address whether such vaccine constructs could enhance 
pre-existing BCG-mediated immunity in the mouse model in a 
prime-boost immunization schedule. In the present study, we 
used a technologically superior low-dose aerosol Mtb challenge 
model to test the efficacy of a novel TB vaccine, Spore-FP1, on 
BCG-immunized mice, with the hypothesis that Spore-FP1 could 
boost the protection afforded by BCG. Spore-FP1 was designed 
to include antigens expressed during the early (Ag85B) and late 
(ACR) phases of Mtb infection, which could help to account for 
some of the observed dynamic changes in antigen expression dur-
ing disease (39). Moreover, unlike previous studies, Spore-FP1 
also contained a portion of the epithelium-binding domain of 
HBHA, which would encourage attachment to lung epithelium 
and dissemination of the vaccine (40).
Our most important finding was that intranasal immunization 
with Spore-FP1 in a BCG-primed mouse (i.e., the “prime-boost” 
strategy) could significantly enhance protection above that given 
by BCG alone. This effect was independent of any coadjuvants or 
whether the spores were viable or not. Bacterial burdens in the 
lungs were significantly reduced by the Spore-FP1 booster immu-
nization compared to BCG alone. Interestingly, there was no sta-
tistically significant reduction in extra-pulmonary Mtb. This may 
reflect a limitation of detection in our assays, or at least an area 
of potential development for future utilization of spore vehicle 
systems. Distinct T-cell-derived cytokine patterns are known to 
exert dichotomous effects on bacterial burdens in the lungs and 
spleen (41), which may be the case here. Furthermore there was 
also a slight reduction in protective effect when Spore-FP1 was 
used with adjuvant. This may reflect ordinary biological variation 
between experiments, or perhaps non-optimal adjuvant choice, 
and will be the subject of future investigations.
To investigate immunological events associated with protec-
tion, we first evaluated antigen-dependent antibody production 
in serum and BAL. The role of antibodies in TB is contentious, 
although there have been recent reappraisals of the field gener-
ally in favor of their protective role (42). Mice immunized with 
Spore-FP1 were found to produce more Ag85B-specific IgG in 
the serum and IgA in the BAL than the BCG group; a similar 
FigUre 6 | Bacillus subtilis spores activate antigen-presenting cells. (a) Dendritic cells (DCs) (left) and macrophages (right) were stimulated in duplicate for 48 h with 
LPS (100 ng/mL) or B. subtilis spores (1, 10, and 100 MOI) and surface molecule expression was measured by flow cytometry on gated viable cells. MFI was normalized 
to the unstimulated control. (B) Cytokines from the supernatants were tested for proinflammatory cytokine production by ELISA. (c) Macrophages were stimulated for 
20 h with LPS (100 ng/mL) or B. subtilis spores (100 MOI) in the presence of brefeldin A (10 µg/mL), followed by intracellular detection of IL-12p40. EC, empty channel. 
A representative experiment is shown. (D) Transcription factor phosphorylation levels were determined by PhosphoFlow. Macrophages were stimulated with 100 ng/mL 
LPS (blue histograms) or 100 MOI spores (red histograms) for 4 h and then fixed and stained. Some cells were left untreated (black histograms). Representative MFI 
values are plotted on the relevant histogram. Data are from three (a–c) or one (D) independent experiments. Results are expressed as mean ± SEM. Significance was 
tested against the unstimulated control by one-way ANOVA with Fisher’s posttest, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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trend was observed for ACR. These data strongly suggest that a 
Spore-FP1 boost immunization was better at inducing humoral 
immunity than a single BCG immunization.
T-cells are essential for protection against Mtb: Th1 cells prime 
macrophages for activation via IFN-γ (43), and Th17  cells can 
upregulate the production of antimicrobial peptides and lym-
phocyte chemoattractants (44, 45). Deficiency in either of these 
cytokines is extremely detrimental to the host during disease. 
It has been shown that during natural infection, Mtb can subvert 
the host immune system in order to restrict antigen presentation 
(46, 47). Hence a vaccine that enhances antigen presentation, 
and thus leads to a higher frequency of antigen-specific T-cells, 
is highly desirable. In our experiments, we observed a higher 
frequency of proliferating splenic T-cells in response to recall 
antigens in the Spore-FP1 group compared to mice that had 
only received BCG immunization. BCG is also able to restrict 
antigen presentation in  vivo to a certain extent (47–49), and 
consistent with this fact, we observed minimal proliferative 
responses to Ag85B/ACR in BCG-immunized animals. Such 
small-magnitude responses in BCG-immunized mice are highly 
typical and described elsewhere in the literature, wherein cells 
specific for Ag85 typically represent ~0.1% of the total sple-
nic polyclonal T-cell pool in cytokine capture assays (31, 32). 
In contrast to these constrained responses, Spore-FP1 was able to 
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induce a dramatically larger percentage of proliferating T-cells, 
indicating either a higher frequency of memory cells, or at the 
very least cells with a higher proliferative capacity. Many of the 
proliferating CD8+ Ki67+ cells were of the Tcm phenotype, which 
act as a “reservoir” of cells in primary and secondary lymphoid 
organs with high potential for differentiation into effector cells 
in distal sites. For chronic diseases such as TB that include 
T-cell exhaustion as a definitive mechanism of immune evasion 
(i.e., terminal differentiation), the generation of proliferative Tcm 
by a prophylactic vaccine offers a distinct advantage.
In line with proliferative responses, Spore-FP1 was also a 
potent inducer of IFN-γ, IL-10, and IL-17A release after spleno-
cyte exposure to recall antigens. Thus, the antigen-specific cells 
were fully functional by producing effector cytokines during 
proliferation. It could be surmised that Spore-FP1 therefore 
induced a mixed Th1-Th17-Treg response. The absence of IL-4 
release is interesting, and suggests that Spore-FP1 induced a 
T-cell skewing away from the Th2 to a Th1/Th17 phenotype. 
IL-4 is largely believed to be detrimental during Mtb infection, 
since it antagonizes the biological effects of IFN-γ to promote 
alternatively activated macrophages (50). The role of IL-10 in TB 
is more contentious. While IL-10 can hamper antimycobacte-
rial immunity during BCG immunization (51), recent evidence 
from Rhesus macaque infection models has suggested that CD4+ 
T-cells coexpressing a balance of pro- and anti-inflammatory 
cytokines are significantly associated with granuloma steriliza-
tion, possibly due to a reduction in “collateral damage” to the lung 
tissue (52). Furthermore, IL-10 is important for shielding CD8+ 
memory T-cells from apoptosis in inflammatory contexts (53), 
and IL-10 deficient mice are highly susceptible to reinfection by 
intracellular pathogens (54). We believe that the T-cell profile 
induced by Spore-FP1 is therefore beneficial in the context of 
immunization.
It is worth noting that for both humoral and cellular immu-
nogenicity, there was generally a greater response to Ag85B than 
to ACR. This is perhaps due to the fact that Ag85B is a strong 
immunodominant antigen (55) that has formed the basis of 
many new TB vaccines. Notably, however, ACR was still able to 
elicit potent IFN-γ production in splenocytes from Spore-FP1-
immunized mice.
Alongside conventional T-cell activation signatures, we also 
observed a striking accumulation of gross CD69+CD103+ Trm 
in lung tissue after immunization with Spore-FP1. These cells are 
likely to be directed toward epitopes found within FP1, since the 
vehicle control (spores alone) failed to induce any appreciable 
quantities of these cells. As to why no Trm were directed against 
B. subtilis spores themselves, it may be that B. subtilis, as a mam-
malian commensal (56) (in the absence of a “foreign” antigen 
such as those included in FP1), can suppress the mobilization of 
effector T-cells that would lead to its own clearance. In support 
of this hypothesis, B. subtilis secretory products can induce a 
Foxp3-dependent tolerogenic environment in the gut (57), and 
consistent with this fact, we observed modest IL-10 responses 
from splenocytes exposed to recall antigen (although much lower 
than IFN-γ and IL-17A). A recent study has elegantly demon-
strated that mucosal immunization with BCG—as opposed to 
parenteral immunization—leads to the accumulation of Trm in 
the pulmonary tissue (27). These cells are sufficient for protec-
tion, since adoptive transfer of Trm into BCG-naive mice protects 
against Mtb challenge. We speculate that the enrichment of this 
cell type in the lungs, induced by Spore-FP1 in our experiments, 
is playing a major role in the protection afforded by our novel 
vaccine.
Turning our attention to the innate immune system, we detec-
ted potent activation signatures in macrophages and DCs pulsed 
with B. subtilis spores. While it is known that B. subtilis spores 
can activate TLR-2→MyD88 downstream pathways, these stud-
ies have largely restricted maturation marker analysis to CD40 
and MHC Class I and II expression on DCs (19, 58). Here, we 
showed for the first time that spores can also simultaneously 
induce CCR7, PD-L1 and PD-L2 upregulation. Since minimal 
T-cell priming occurs in the lung (59, 60), CCR7 expression will 
be critical for DCs that have taken up Spore-FP1 to migrate to 
the lung-draining lymph nodes and present antigen to naive 
T-cells. The upregulation of PD-L1 and PD-L2, on the other 
hand, may mitigate the overall inflammatory response, which is 
an important boon for mucosal delivery. In justification of this 
notion, PD-L1 blockade during antigen delivery into the lungs 
leads to exacerbated irritation and inflammation via Treg deple-
tion, which is ameliorated upon immune reconstitution (61). 
Underscoring all of these phenotypic characteristics was the 
observation that IRF-3 was phosphorylated alongside NF-κB 
upon APC stimulation with spores. These data allude to a novel 
activation pathway besides the TLR-2→MyD88 axis, which is 
driving APC activation by B. subtilis spores, and has hitherto 
remained unexplored. This proposition warrants further bio-
chemical investigation.
To conclude, we have shown that Spore-FP1 can enhance 
protection offered by BCG and also activate multiple arms of the 
innate and adaptive immune systems. These data demonstrate 
the potential applicability of Spore-FP1 as a TB vaccine, but also 
offer fresh insights into the mechanisms of B. subtilis spores as a 
vaccine development platform.
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